BCM
DNA icon

Bayesian Capital Management’s Ginkgo Bioworks DNA Stock Holding History

Bayesian Capital Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-555
Closed -$7.42K – 767
2024
Q2 		$7.42K Buy
555
+97
+21% +$2.89K ﹤0.01% 682
2024
Q1 		$21.2K Buy
+458
New +$23.7K ﹤0.01% 745
2023
Q4 		– Sell
-595
Closed -$43.1K – 818
2023
Q3 		$43.1K Buy
+595
New +$47.6K ﹤0.01% 640
2022
Q2 		– Sell
-1,093
Closed -$176K – 846
2022
Q1 		$176K Buy
1,093
+388
+55% +$75.5K 0.03% 668
2021
Q4 		$234K Buy
+705
New +$335K 0.07% 294

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Bayesian Capital Management's DNA Position: Q3 2024 in Review

Bayesian Capital Management sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 555 shares — an estimated $7.42K sold.

Bayesian Capital Management first reported a position in DNA in Q4 2021 and held it in 5 quarters. The position peaked at $234K in Q4 2021. 159 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

  • Bayesian Capital Management reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
  • Bayesian Capital Management sold 555 Ginkgo Bioworks shares in Q3 2024, an estimated $7.42K.
  • Bayesian Capital Management first reported a position in Ginkgo Bioworks in Q4 2021 and held it in 5 quarters.
  • Bayesian Capital Management's Ginkgo Bioworks position peaked at $234K in Q4 2021.
  • 159 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on Bayesian Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.